Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Fig 1
NKTR-214 delivers a controlled, sustained, and biased signal through the IL2 receptor pathway.
NKTR-214 is a CD122-biased cytokine agonist conjugated with multiple releasable chains of PEG located at the interface of IL2 and IL2Rαβγ. The PEG chains slowly release at physiological pH, creating conjugated-IL2 species with fewer PEG chains and increased bioactivity. Sustained signaling through the heterodimeric IL2 receptor pathway (IL2Rβγ) preferentially activates and expands effector CD8 T and NK cells over Tregs.